|
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) DCF Valoración
CN | Healthcare | Drug Manufacturers - General | SHZ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) Bundle
Ya sea que sea un inversor o un analista, esta calculadora DCF (300357SZ) es su recurso de referencia para una valoración precisa. Cargados con datos reales de Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., puede ajustar los pronósticos y observar instantáneamente los efectos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 639.4 | 636.2 | 807.7 | 896.0 | 848.2 | 916.2 | 989.6 | 1,068.9 | 1,154.6 | 1,247.1 |
| Revenue Growth, % | 0 | -0.49184 | 26.95 | 10.94 | -5.34 | 8.01 | 8.01 | 8.01 | 8.01 | 8.01 |
| EBITDA | 328.7 | 339.2 | 422.4 | 425.3 | 391.1 | 459.2 | 496.0 | 535.7 | 578.7 | 625.0 |
| EBITDA, % | 51.41 | 53.31 | 52.3 | 47.46 | 46.11 | 50.12 | 50.12 | 50.12 | 50.12 | 50.12 |
| Depreciation | 10.8 | 16.5 | 27.0 | 28.0 | 39.4 | 28.2 | 30.5 | 32.9 | 35.6 | 38.4 |
| Depreciation, % | 1.7 | 2.59 | 3.35 | 3.13 | 4.65 | 3.08 | 3.08 | 3.08 | 3.08 | 3.08 |
| EBIT | 317.8 | 322.7 | 395.4 | 397.3 | 351.7 | 430.9 | 465.5 | 502.8 | 543.1 | 586.6 |
| EBIT, % | 49.71 | 50.72 | 48.95 | 44.34 | 41.46 | 47.04 | 47.04 | 47.04 | 47.04 | 47.04 |
| Total Cash | 792.1 | 890.7 | 1,020.9 | 1,135.7 | 1,288.8 | 916.2 | 989.6 | 1,068.9 | 1,154.6 | 1,247.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 198.2 | 226.7 | 238.1 | 254.3 | 202.9 | 272.0 | 293.8 | 317.3 | 342.7 | 370.2 |
| Account Receivables, % | 31.01 | 35.63 | 29.48 | 28.38 | 23.92 | 29.69 | 29.69 | 29.69 | 29.69 | 29.69 |
| Inventories | 36.8 | 48.3 | 53.8 | 48.4 | 59.0 | 59.3 | 64.1 | 69.2 | 74.8 | 80.7 |
| Inventories, % | 5.76 | 7.6 | 6.65 | 5.4 | 6.96 | 6.47 | 6.47 | 6.47 | 6.47 | 6.47 |
| Accounts Payable | 8.7 | 5.7 | 5.1 | 7.7 | 8.0 | 8.6 | 9.3 | 10.0 | 10.8 | 11.7 |
| Accounts Payable, % | 1.36 | 0.89019 | 0.62956 | 0.85743 | 0.94224 | 0.93555 | 0.93555 | 0.93555 | 0.93555 | 0.93555 |
| Capital Expenditure | -99.8 | -70.2 | -122.2 | -188.7 | -209.2 | -160.3 | -173.2 | -187.0 | -202.0 | -218.2 |
| Capital Expenditure, % | -15.61 | -11.03 | -15.12 | -21.06 | -24.66 | -17.5 | -17.5 | -17.5 | -17.5 | -17.5 |
| Tax Rate, % | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 |
| EBITAT | 274.2 | 278.5 | 340.1 | 347.5 | 315.3 | 375.5 | 405.6 | 438.2 | 473.3 | 511.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -41.1 | 181.8 | 227.5 | 178.5 | 186.6 | 174.7 | 237.1 | 256.1 | 276.6 | 298.8 |
| WACC, % | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 977.4 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 308 | |||||||||
| Terminal Value | 6,263 | |||||||||
| Present Terminal Value | 4,279 | |||||||||
| Enterprise Value | 5,257 | |||||||||
| Net Debt | -1,109 | |||||||||
| Equity Value | 6,365 | |||||||||
| Diluted Shares Outstanding, MM | 524 | |||||||||
| Equity Value Per Share | 12.16 |
What You Will Receive
- Authentic Zhejiang Wolwo Data: Preloaded financial metrics – from revenue to EBIT – grounded in both actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth rates, and tax percentages.
- Immediate Valuation Refreshes: Automatic recalculations to assess how changes affect the fair value of Zhejiang Wolwo (300357SZ).
- Flexible Excel Template: Designed for quick adjustments, scenario analysis, and in-depth projections.
- Efficient and Precise: Bypass the need to construct models from the ground up while ensuring accuracy and adaptability.
Key Features
- Authentic Financial Data for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.: Gain access to precise historical figures and future forecasts.
- Adjustable Projection Variables: Modify the highlighted yellow cells to tailor WACC, growth rates, and profit margins.
- Real-Time Calculations: Benefit from automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Visual Dashboard: Clear and informative charts and summaries to help you interpret your valuation findings.
- Designed for All Experience Levels: An accessible and intuitive layout suitable for investors, CFOs, and consultants alike.
How It Functions
- Step 1: Download the Excel workbook.
- Step 2: Examine the pre-filled financial information and projections for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357SZ).
- Step 3: Adjust essential variables such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for your investment strategies.
Why Choose This Tool for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357SZ)?
- Reliable Information: Authentic financial data from Zhejiang Wolwo supports trustworthy valuation outcomes.
- Fully Customizable: Tailor essential metrics such as growth rates, discount rates, and tax rates to fit your forecasts.
- Efficient: Ready-made calculations save you from having to build your analysis from the ground up.
- Expert-Level Resource: Built for investors, financial analysts, and consultants working with (300357SZ).
- User-Friendly Design: A straightforward interface and clear instructions make it accessible to everyone.
Who Can Benefit from This Product?
- Pharmaceutical Students: Discover biopharmaceutical valuation methods and apply them using real market data.
- Researchers: Integrate industry-standard models into your academic studies or clinical research.
- Investors: Assess your own hypotheses and evaluate valuation predictions for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357SZ).
- Market Analysts: Enhance your efficiency with a pre-designed, customizable DCF model tailored for the biopharmaceutical sector.
- Entrepreneurs in Healthcare: Understand the analytical approaches used for evaluating substantial public enterprises like Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357SZ).
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357SZ), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that display intrinsic value along with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate comprehensive analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357SZ).
- Dashboard and Charts: Visual representation of valuation results and assumptions for easy analysis of outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.